Fernández-Real J M, Ricart W, Porcar C, Teruel J
Sección de Endocrinología, Hospital Universitario Dr. Josep Trueto, Girona.
Rev Clin Esp. 1998 Jan;198(1):28-32.
Some patients with primary hypothyroidism (HP) develop massive thyrotrope cell hyperplasia determining pituitary hyperplasia with suprasellar enlargement and pituitary dysfunction. Although TRH secretion undoubtedly has some influence, the intervention of other possible factors determining this hyperplasia and dysfunction has been little assessed.
Two patients with primary hypothyroidism with a serum TSH > 1,000 mU/I were studied. By means of CT and MR a pituitary hyperplasia was ascertained in the two patients. The pituitary functional reserve was investigated by the serum response of TSH and prolactin to the administration of TRH (400 micrograms, i.v.), bromocriptine (BRC, 5 mg, oral route), somatostatine (ST, 50 micrograms/kg/min, i.v. perfusion), and gonadotropin releasing hormone (GnRH, 100 micrograms, i.v.).
The TRH induced increment of TSH was 145% and 193%, respectively, compared with basal values. After the administration of BRC, TSH decreased to 57% and 84% of basal values, and PRL to 46% and 43%, respectively. TSH and PRL concentrations did not change after the administration of ST or GnRH. In both cases, hyperplasia and pituitary dysfunction returned to normality after substitutive therapy with levothyroxine.
Basal hyperprolactinemia and TSH and PRL responses to BRC administration suggest that central dopaminergic activity is decreased or abolished in patients with HP and pituitary hyperplasia. The massive thryrotrope cell hyperplasia and hypothyroidism itself determine pituitary dysfunction, which reverts after therapy with levothyroxine, a fact which is scarcely documented in literature.
一些原发性甲状腺功能减退症(HP)患者会出现促甲状腺激素细胞大量增生,导致垂体增生并伴有鞍上扩大和垂体功能障碍。尽管促甲状腺激素释放激素(TRH)分泌无疑有一定影响,但对决定这种增生和功能障碍的其他可能因素的干预评估甚少。
研究了两名血清促甲状腺激素(TSH)>1000 mU/I的原发性甲状腺功能减退症患者。通过CT和磁共振成像(MR)确定两名患者均有垂体增生。通过检测TSH和催乳素(PRL)对静脉注射TRH(400微克)、口服溴隐亭(BRC,5毫克)、静脉输注生长抑素(ST,50微克/千克/分钟)和静脉注射促性腺激素释放激素(GnRH,100微克)的血清反应来研究垂体功能储备。
与基础值相比,TRH诱导的TSH增量分别为145%和193%。服用BRC后,TSH分别降至基础值的57%和84%,PRL分别降至基础值的46%和43%。服用ST或GnRH后,TSH和PRL浓度未发生变化。在这两个病例中,用左甲状腺素替代治疗后,增生和垂体功能障碍均恢复正常。
基础高催乳素血症以及TSH和PRL对BRC给药的反应表明,HP和垂体增生患者的中枢多巴胺能活性降低或丧失。大量促甲状腺激素细胞增生和甲状腺功能减退本身决定了垂体功能障碍,而左甲状腺素治疗后这种功能障碍会恢复,这一事实在文献中鲜有记载。